Literature DB >> 30611529

Device-detected congestion is associated with worse patient-reported outcomes in heart failure.

Jonathan P Auld1, James O Mudd2, Jill M Gelow2, Karen S Lyons3, Shirin O Hiatt3, Christopher S Lee4.   

Abstract

BACKGROUND: Congestion is a common cause of symptoms in heart failure (HF). Yet, intrathoracic impedance, an objective marker of cardiopulmonary congestion, has not been examined in relation to HF symptoms.
OBJECTIVE: To determine whether device-detected cardiopulmonary congestion is a predictor of physical and psychological symptoms and health-related quality of life (HRQOL) in adults with HF over 3 months.
METHODS: Multivariate generalized linear modeling was used to quantify the association of cardiopulmonary congestion (Optivol® Index exceeding 60 Ω threshold) with HRQOL (12-item Kansas City Cardiomyopathy Questionnaire) and both physical symptoms (Functional Assessment of Chronic Illness Therapy-Fatigue Scale; HF Somatic Perception Scale Dyspnea and Early & Subtle Symptoms subscales) and affective symptoms (9-item Patient Health Questionnaire; 6-item Patient-Reported Outcomes Measurement Information System Anxiety Scale).
RESULTS: The mean age of the sample (n = 49) was 62years old, 39% were women, and 63% had NYHA class III/IV HF. Participants who experienced threshold crossings in the previous 90days reported on average, 130% higher dyspnea (p = 0.017; confidence interval (CI) 10.2%, 437%), 40% higher early & subtle symptoms (p = 0.029; CI 3.4%, 89.7%), 106% higher depressive symptoms (p = 0.003; CI 19.1%, 257%) and 40% higher anxiety (p = 0.028; CI 3.7%, 89.1%). Threshold crossings in the previous 90days were also significantly associated with a clinically meaningful decrease in HRQOL (β = -16.16 ± 6.32; p = 0.01).
CONCLUSIONS: Intrathoracic impedance measured with the Optivol Index can provide additional information regarding the patient experience of hallmark physical and psychological HF symptoms and HRQOL over 3months.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; Intrathoracic impedance; Pulmonary congestion; Quality of life; Symptom

Mesh:

Year:  2019        PMID: 30611529      PMCID: PMC8205296          DOI: 10.1016/j.hrtlng.2018.12.003

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  49 in total

1.  Somatic awareness, uncertainty, and delay in care-seeking in acute heart failure.

Authors:  Corrine Y Jurgens
Journal:  Res Nurs Health       Date:  2006-04       Impact factor: 2.228

2.  Why do elders delay responding to heart failure symptoms?

Authors:  Corrine Y Jurgens; Linda Hoke; Janet Byrnes; Barbara Riegel
Journal:  Nurs Res       Date:  2009 Jul-Aug       Impact factor: 2.381

3.  A qualitative meta-analysis of heart failure self-care practices among individuals with multiple comorbid conditions.

Authors:  Victoria Vaughan Dickson; Harleah Buck; Barbara Riegel
Journal:  J Card Fail       Date:  2011-01-21       Impact factor: 5.712

4.  Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST).

Authors:  William T Abraham; Steven Compton; Garrie Haas; Blair Foreman; Robert C Canby; Robert Fishel; Scott McRae; Gloria B Toledo; Shantanu Sarkar; Douglas A Hettrick
Journal:  Congest Heart Fail       Date:  2011-03-21

5.  Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure.

Authors:  Monica R Shah; Vic Hasselblad; Sandra S Stinnett; Judith M Kramer; Steven Grossman; Mihai Gheorghiade; Kirkwood F Adams; Karl Swedberg; Robert M Califf; Christopher M O'Connor
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

6.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

7.  Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.

Authors:  Eldrin F Lewis; Gervasio A Lamas; Eileen O'Meara; Christopher B Granger; Mark E Dunlap; Robert S McKelvie; Jeffrey L Probstfield; James B Young; Eric L Michelson; Katarina Halling; Jonas Carlsson; Bertil Olofsson; John J V McMurray; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Journal:  Eur J Heart Fail       Date:  2006-12-21       Impact factor: 15.534

8.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

9.  Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life.

Authors:  Thomas S Rector; Inder S Anand; Jay N Cohn
Journal:  J Card Fail       Date:  2006-03       Impact factor: 5.712

10.  Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure.

Authors:  Cheryl Hoyt Zambroski; Debra K Moser; Geetha Bhat; Craig Ziegler
Journal:  Eur J Cardiovasc Nurs       Date:  2005-09       Impact factor: 3.908

View more
  2 in total

1.  Identifying unique profiles of perceived dyspnea burden in heart failure.

Authors:  Kenneth M Faulkner; Corrine Y Jurgens; Quin E Denfeld; Karen S Lyons; Jessica Harman Thompson; Christopher S Lee
Journal:  Heart Lung       Date:  2020-05-18       Impact factor: 2.210

2.  The first survey on patient needs for remote monitoring of cardiac implantable electronic device in South Korea.

Authors:  You Mi Hwang; Ji-Hoon Kim
Journal:  Medicine (Baltimore)       Date:  2022-06-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.